GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 2, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in JAMA Ophthalmology.
Nitesh Mohan, from the Cole Eye Institute at the Cleveland Clinic, and colleagues examined whether being prescribed a GLP-1 RA is associated with a reduced risk for developing uveitis in a retrospective cohort study using electronic health record network data from 2006 to 2025.
The study included 516,052 patients: 258,026 in the GLP-1 RA group and 258,026 in the propensity score-matched control group. The researchers found that compared with controls, the GLP-1 RA cohort had a reduced risk for uveitis (risk ratio, 0.48), which was consistent among those with type 2 diabetes and without diabetes (risk ratios, 0.54 and 0.52, respectively). GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin (risk ratios, 0.58 and 0.57, respectively). Compared with those taking sodium-glucose cotransporter 2 inhibitors (SGLT2is), patients taking GLP-1 RAs had a slightly increased uveitis risk (risk ratio, 1.17); SGLT2i prescriptions were associated with a reduced risk for uveitis compared with controls (risk ratio, 0.52).
"This is the first study to find a protective effect of GLP-1 RA therapy for autoimmune disease, which is very exciting and shows a further benefit of these drugs for patients beyond just weight loss and control of diabetes,” senior study author Sumit Sharma, M.D., also from the Cleveland Clinic Cole Eye Institute, said in a statement.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2025
Read this next
AI-Enabled Bundle of Sensors, Coaching Aids Type 2 Diabetes Outcomes
THURSDAY, Aug. 28, 2025 -- An artificial intelligence (AI)-enabled bundled system of sensors and coaching facilitates significant improvements in glycemic outcomes and...
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 -- For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower...
MedDiet Plus Energy Reduction, Physical Activity Cuts Incidence of Type 2 Diabetes
TUESDAY, Aug. 26, 2025 -- For individuals with overweight or obesity and metabolic syndrome, an intensive intervention combining energy reduction, the Mediterranean diet...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.